Free Trial

Nevro (NVRO) Stock Forecast & Price Target

Nevro logo
$3.79 +0.20 (+5.57%)
(As of 12/20/2024 05:31 PM ET)

Nevro - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
3
Hold
10
Buy
0

Based on 13 Wall Street analysts who have issued ratings for Nevro in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 13 analysts, 3 have given a sell rating, and 10 have given a hold rating for NVRO.

Consensus Price Target

$6.30
66.23% Upside
According to the 13 analysts' twelve-month price targets for Nevro, the average price target is $6.30. The highest price target for NVRO is $16.00, while the lowest price target for NVRO is $4.00. The average price target represents a forecasted upside of 66.23% from the current price of $3.79.
Get the Latest News and Ratings for NVRO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Nevro and its competitors.

Sign Up

NVRO Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
3 Buy rating(s)
Hold
10 Hold rating(s)
11 Hold rating(s)
11 Hold rating(s)
9 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$6.30$9.10$10.63$24.23
Forecasted Upside66.23% Upside105.21% Upside81.65% Upside12.65% Upside
Consensus Rating
Reduce
Reduce
Reduce
Hold

NVRO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVRO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Nevro Stock vs. The Competition

TypeNevroMedical CompaniesS&P 500
Consensus Rating Score
1.77
2.81
2.51
Consensus RatingReduceModerate BuyModerate Buy
Predicted Upside66.23% Upside25,828.56% Upside14.54% Upside
News Sentiment Rating
Neutral News

See Recent NVRO News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/18/2024Truist Financial
2 of 5 stars
 Lower TargetHold ➝ Hold$7.00 ➝ $4.70+18.09%
12/11/2024Citigroup
3 of 5 stars
J. Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$6.00 ➝ $5.00+16.28%
12/11/2024Wells Fargo & Company
3 of 5 stars
N. Treybeck
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$5.00 ➝ $4.00-6.32%
12/9/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$7.00 ➝ $4.00-8.88%
12/2/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeEqual Weight ➝ Underweight$9.00 ➝ $4.00-13.04%
11/12/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Turkaly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
11/12/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSector Perform ➝ Sector Perform$7.00 ➝ $7.00+10.41%
11/12/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$7.00 ➝ $6.00+12.57%
11/12/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$5.00 ➝ $6.00+12.57%
8/8/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Polark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Peer Perform
8/7/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight
4/11/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$20.00 ➝ $16.00+20.30%
2/22/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:10 AM ET.


NVRO Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Nevro is $6.30, with a high forecast of $16.00 and a low forecast of $4.00.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 3 sell ratings and 10 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" NVRO shares.

According to analysts, Nevro's stock has a predicted upside of 66.23% based on their 12-month stock forecasts.

Over the previous 90 days, Nevro's stock had 1 downgrade by analysts.

Analysts like Nevro less than other "medical" companies. The consensus rating for Nevro is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVRO compares to other companies.


This page (NYSE:NVRO) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners